High Prevalence of Industry Ties in the US Cancer Ecosystem
Publication Title: Prevalence of industry ties in the US cancer ecosystem: a systematic review and meta-analysis
Summary
- Question
- This study examined the prevalence of financial conflicts of interest (FCOI) across multiple sectors of the United States cancer ecosystem. Specifically, the researchers aimed to quantify FCOI among six groups: clinical trial researchers, U.S. Food and Drug Administration (FDA) meeting participants, academic medical leaders, patient advocacy organizations, authors of clinical practice guidelines, and practicing oncologists.
- Why it Matters
- Financial conflicts of interest occur when individuals or organizations have financial relationships with industry—such as funding, consulting fees, or other payments—that could influence their professional judgment. In oncology, where cancer treatments and guidelines directly impact patient care, high rates of FCOI raise concerns about impartiality in clinical decision-making, research integrity, and patient outcomes. Understanding the extent of FCOI is critical for maintaining trust in cancer care and ensuring evidence-based practices that prioritize patient health over industry interests.
- Methods
- The researchers conducted a systematic review and meta-analysis of studies published since 2015. They searched five major scientific databases for studies reporting FCOI prevalence in oncology-related domains. Eligible studies were reviewed by two independent researchers to extract data, and random-effects meta-analyses were performed for domains with at least five studies. The analysis focused on both narrative summaries and pooled prevalence rates for industry ties in clinical trials and practicing oncologists.
- Key Findings
- The study found that financial conflicts of interest were widespread across the U.S. cancer ecosystem. Among the six domains examined, over 50% of studies reported high prevalence of FCOI. For clinical trials, industry sponsorship ranged from 36.8% to 89%, with a pooled prevalence of 69%. Among practicing oncologists, industry payments ranged from 24.7% to 100%, with a pooled prevalence of 61%. Other domains, such as FDA meeting speakers and academic medical leaders, showed prevalence rates as high as 92.1% and 100%, respectively. Patient advocacy organizations and guideline authors also exhibited significant FCOI rates, with some exceeding 98%.
- Implications
- The findings suggest that financial conflicts of interest are pervasive across critical areas of oncology, potentially influencing research priorities, clinical guidelines, and patient care. This underscores the need for increased transparency and stricter regulations to mitigate the impact of industry ties on healthcare decisions. Addressing these conflicts is vital to ensuring that cancer treatment and policy decisions are guided by unbiased evidence and prioritizing patient outcomes.
- Next Steps
- The authors emphasized the importance of continued monitoring of financial conflicts of interest in oncology and recommended further research to explore the effects of FCOI on clinical decision-making and patient care outcomes. They also called for stronger policies to manage and disclose industry relationships across all domains of the cancer ecosystem.
- Funding Information
Yale University provided funding and support for this research. View the full paper at https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djag175/8733774?redirectedFrom=fulltext
Full Citation
Kim C, Waddell L, Nemeth Z, Gross C. Prevalence of industry ties in the US cancer ecosystem: a systematic review and meta-analysis. Journal Of The National Cancer Institute 2026, djag175. PMID: 42448352, DOI: 10.1093/jnci/djag175.
Authors
Colin J Kim
First AuthorCary P Gross, MD
Last AuthorProfessor of Medicine (General Medicine) and of Epidemiology (Chronic Diseases)
Additional Yale School of Medicine Authors
Other Authors
Research Themes
Concepts
- clinical practice guidelines;
- prevalence of financial conflicts;
- patient advocacy organizations;
- pooled prevalence;
- medical leaders;
- practice guidelines;
- systematic review;
- financial conflicts;
- primary research studies;
- advocacy organizations;
- meta-analysis;
- authors of clinical practice guidelines;
- healthcare administrative databases;
- practicing oncologists;
- cancer clinical trials;
- Web of Science;
- clinical decision-making;
- narrative summary;
- clinical trials;
- administrative databases;
- extraction form;
- eligible articles;
- Ovid MEDLINE;
- patient outcomes;
- Ovid Embase